DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,903,068 B1 Stanton Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,903,068 B1 Stanton Et Al USOO6903068B1 (12) United States Patent (10) Patent No.: US 6,903,068 B1 Stanton et al. (45) Date of Patent: *Jun. 7, 2005 (54) USE OF COLOSTRININ, CONSTITUENT OTHER PUBLICATIONS PEPTIDES THEREOF, AND ANALOGS THEREOF FOR INDUCING CYTOKINES Kruzel et al. (Dec. 2001) “Towards an Understanding of Biological Role of Colonstrinin Peptides.” Journal of (75) Inventors: G. John Stanton, Texas City, TX (US); Molecular Neuroscience 17(3): 379–389.* Thomas K. Hughes, Jr., Galveston, TX Inglot, Junsz, and Lisowski Colostrinine: a Proline-Rich (US); Istvan Boldogh, Galveston, TX Polypeptide from Ovine Colostrum Is a Modest Cytokine (US); Jerzy A. Georgiades, Houston, Inducer in Human Leukocytes, 1996, Archivum Immuno TX (US) logiae et Therapiae Experimentalis (44) 215-224.* Elgert, "Immunology: Understanding the Immune System” (73) Assignee: Board of Regents, The University of Text (1996) Wiley-Liss 1st Ed. pp. 24–26 and 199-217.* Texas System, Austin, TX (US) Ngo et al. Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox (1994) The Protein (*) Notice: Subject to any disclaimer, the term of this Folding Problem and Teriary Structure Prediction (#14), patent is extended or adjusted under 35 491-495. U.S.C. 154(b) by 488 days. Wells Addivity of Mutational Effects in Proteins (1990) Biochemistry (29): 37,8509-8517.* This patent is Subject to a terminal dis- Babbit, ed., The Vanderbilt Rubber Handbook, R.T. Vander claimer. bilt Company, Inc., Norwalk, CT, pp. 344-397 (1978). Bespalov et al., “Fabs Specific for 8-oxoguanine: control of (21) Appl. No.: 09/641,801 DNA binding.” J Mol Biol. Nov. 12, 1999:293(5):1085–95. (22) Filed: Aug. 17, 2000 Blach-Olszewska et al., “Stimulatory effect of ovine colos e -- is trinine (a proline-rich polypeptide) on interferons and tumor Related U.S. Application Data necrosis factor production by murine resident peritoneal cells.” Arch Immunol Ther Exp (Warsz). 1997; 45(1):43–7. (60) Continuation-in-part of application No. 10/281,652, filed on Buescher et al., “Clostral antioxidants: Separation and char Oct. 28, 2002, which is a division of application No. acterization of two activities in human colostrum, J Pediatr 09/641,803, filed on Aug. 17, 2000, now Pat. No. 6,500,798. Gastroenterol Nutr1. Jan. 1992; 14(1):47-56. (60) Provisional application No. 60/420,369, filed on Oct. 22, 2002, and provisional application No. 60/149,311, filed on Calingasan et al., "Protein-bound acrolein: a novel marker Aug. 17, 1999. of oxidative stress in Alzheimer's disease,” J. Neurochem. Feb. 1999;72(2):751–6. (51) Int. Cl." ........................ A61K 38/00; A61K 38/02; Chao “Growth factor signaling: where is the specificity'?” A61K 38/08; A61K 38/18 Cell. Mar. 20, 1992; 68(6): 995–7. (52) U.S. Cl. ............................... 514/2; 514/12; 514/13; Esterbauer et al., “Chemistry and biochemistry of 4-hydrox 514/14: 514/15; 514/16; 514/17; 530/300; ynonenal, malonaldehyde and related aldehydes, Free 530/324; 530/326; 530/327; 530/328; 530/329 Radic Biol Med. 1991;11(1):81–128. (58) Field of Search ................................ 514/2, 12, 13, Fields et al., Synthetic Peptides. A User's Guide, W.M. 514/14, 15, 16, 17, 18; 530/300, 324, 326, Freeman & Company, New York, NY, pp. 77-183 (1992). 327, 328,329, 350, 334; 424/85.1,535 Fillmore et al., “Differentiation of PC12 cells with nerve growth factor is associated with induction of transin Syn (56) References Cited thesis and release,” J Neurosci Res. Apr. 1992;31(4):662-9. U.S. PATENT DOCUMENTS Gabbita et al., “Increased nuclear DNA oxidation in the brain in Alzheimer's disease,” J Neurochem. Nov. 4,938,949 A 7/1990 Borch et al. 1998;71(5):2034–40. 6,040,1805,595,887 A 3/20001/1997 JoheCoolidge et al. Gabbita et al., “Decrease66 in peptide methionine Sulfoxide 6,410,058 B2 * 6/2002 Gohlke et al. .............. 424/535 reductase in Alzheimer's disease brain, J Neurochem. Oct. 6,500,798 B1 * 12/2002 Stanton et al. ................. st 1999;73(4): 1660–6. 2003/009 1606 A1 5/2003 Stant t al. f f aO e a (Continued) FOREIGN PATENT DOCUMENTS Primary Examiner Elizabeth C. Kemmerer JP O6 041191 A 2/1994 Assistant Examiner-Christopher James Nichols WO WO95/OO155 1/1995 (74) Attorney, Agent, or Firm- Mueting, Raasch & WO WO95/30686 11/1995 Gebhardt, PA WO WO 98/14473 * 4/1998 s - a. al WO WO 99/65329 12/1999 (57) ABSTRACT WO WOOO/75173 12/2000 WO WO 01/11937 2/2001 The present invention discloses a use of coloStrinin, a W W 8. 2. 2: constituent peptide thereof, and/or an analog thereof as an immunological regulator and as a blood cell regulator in W W 8:45 32: animals including humans. WO WO O2/13851 2/2002 WO WO 03/33423 10/2003 37 Claims, 9 Drawing Sheets US 6,903,068 B1 Page 2 OTHER PUBLICATIONS Lovell et al., “Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease Ventricular Good et al., “Evidence of neuronal Oxidative damage in CSF,” J Neurochem. Feb. 1999;72(2):771–6. Alzheimer's disease,” Am J Pathol. Jul. 1996;149(1):21-8. Lovell et al., “Decreased base excision repair and increased Gratama et al., “Flow cytometric quantitation of immunof helicase activity in Alzheimer's disease brain,” Brain Res. luorescence intensity: problems and perspectives. European Feb. 7, 2000;855(1): 116–23. Working Group on Clinical Cell Analysis,” Cytometry, Oct. Markesberry, “Oxidative stress hypothesis in Alzheimer's 1, 1998:33(2):166–78. disease,” Free Radic Biol Med. 1997:23(1): 134-47. Grunwald et al., “In Situ analysis of chromatin proteins Markesbery et al., “Four-hydroxynonenal, a product of lipid during development and cell differentiation using flow peroxidation, is increased in the brain in Alzheimer's dis cytometry,” Methods Mol Biol. 1999; 119:443–54. ease,” Neurobiol Aging. Jan.-Feb. 1998;19(1):33-6. Hensley et al., "Brain regional correspondence between Markesbery et al. “Oxidative alterations in Alzheimer's Alzheimer's disease histopathology and biomarkers of pro disease,” Brain Pathol. Jan. 1999;9(1):133-46. tein oxidation.” J Neurochem. Nov. 1995; 65(5):2146-56. Marshall et al., “Specificity of receptor tyrosine kinase Hughes et al., “Modulation of immune responses by ana Signaling: transient verSuS Sustained extracellular Signal bolic androgenic steroids.” Int J Immunopharmacol. Nov. regulated kinase activation,” Cell. Jan. 1995 1995;17(11):857–63. 27:80(2):179-85. Inglot et al., “Colostrinine: a proline-rich polypeptide from McHeyzer-Williams et al., “Enumeration and characteriza Ovine colostrum is a modest cytokine inducer in human tion of memory cells in the TH compartment,” Immunol Rev. leukocytes.” Arch Immunol Ther Exp (Warsz). Apr. 1996;150:5-21. 1996;44(4):215-24. Mecocci et al., “Oxidative damage to mitochondrial DNA is Inglot et al., “Colostrinin for treatment of Alzheimer's Alzheimer's disease,” Ann Neurol. Nov. 1994:36(5):747-51. disease,” European Cytokine Network. Sep. Mishell et al., Selected Methods in Cellular Immunology, 1996;7(3):458(abstract 51). W.H. Freeman, San Francisco, CA; title page and table of Inglot et al., "Tumor-associated antigens are cytokine contents only, 9 pages (1980). inducers and hyporeactivity factors to the immune System,” Montine et al., “Cerebrospinal fluid F2-isoprostane levels Biotherapy. 1998;11(1):27–37. are increased in Alzheimer's disease,” Ann Neurol. Sep. JanuSZ et al., “Isolation and characterization of a proli 1998;44(3):410–3. ne-rich polypeptide from Ovine colostrum.” FEBS Lett. Dec. Ostrea et al., “Influence of breast-feeding on the restoration 15, 1974;49(2):276–9. of the low Serum concentration of Vitamin E and beta-caro JanuSZ et al., “Chemical and physical characterization of a tene in the newborn infant,” Am J Obstet Gynecol. May proline-rich polypeptide from sheep colostrum,” Biochem J. 1986;154(5):1014–7. Oct. 1, 1981;199(1): 9-15. Peunova et al., "Nitric oxide triggers a Switch to growth Janusz et al., “Proline-rich polypeptide (PRP)-an immu arrest during differentiation of neuronal cells,” Nature. May nomodulatory peptide from Ovine colostrum, Arch Immu 4, 1995;375(6526):68-73. nol Ther Exp (Warsz). 1993;41(5-6):275–9. Piasecki et al., “Coincidence between Spontaneous release of Kim et al., “Simultaneous differentiation and quantitation of interferon and tumor necrosis factor by colostral leukocytes erythroblasts and white blood cells on a high throughput and the production of a coloStrinine by human mammary clinical haematology analyser,” Clin Lab Haematol. Feb. gland after normal delivery,” Arch Immunol Ther Exp 1998;20(1):21–9. (Warsz), 1997;45(1):109–17. Kooy et al., “Oxidation of 2,7'-dichlorofluorescin by per Popik et al., “Colostrinin, a polypeptide isolated from early oxynitrite,” Free Radic Res. Sep. 1997:27(3):245-54. milk, facilitates learning and memory in rats, Pharmacol LeBel et al., “Evaluation of the probe 2,7'-dichlorofluores Biochem Behav Sep. 1999;64(1):183-9. cin as an indicator of reactive oxygen Species formation and Prasad et al., “Regional membrane phospholipid alterations oxidative stress,” Chem Res Toxicol. Mar.-Apr. in Alzheimer's disease,” Neurochem Res. Jan. 1992:5(2):227–31. 1998:23(1)81–8. Leszek et al., “Colostrinin: a proline-rich polypeptide (PRP) Roberts II et al., “Formation of isoprostane-like compounds complex isolated from Ovine colostrum for treatment of (neuroprostanes) in Vivo from docosahexaenoic acid, J Biol Alzheimer's disease. A double-blind, placebo-controlled Chem. May 29, 1998:273(22): 13605–12. study.” Arch Immunol Ther Exp (Warsz). Rothe et al., “Flow cytometric analysis of respiratory burst 1999;47(6):377-85.
Load more

Recommended publications
  • Información Técnica-Científica Internacional. Relación Del Calostro Bovino Y/O Sus Ingredientes Como Suplemento Alimenticio En Diversas Enfermedades
    Información técnica-científica internacional. Relación del calostro bovino y/o sus ingredientes como suplemento alimenticio en diversas enfermedades Nota: El calostro bovino no es un medicamento ni está clasificado como tal, tampoco está demostrado medicamente que cure o alivie ninguna enfermedad. El uso y el consumo de calostro bovino es una decisión personal y es responsabilidad de quien lo recomienda y de quien lo usa. Estos trabajos aquí incluidos son responsabilidad exclusiva de (los) autor(es) y son presentados con la única intención de educar y como tópicos de interés general, no es intención de la compañía presentarlos como consejo o soporte médico por lo tanto la compañía Schutze-Segen no es responsable en ningún sentido de su contenido. Alergias LeFranc-Millot C, Vercaigne-Marko D, Wal J. -M, et al. (1996) Comparison of the IgE titers to bovine colostral G immunoglobulins and the F(ab')2 fragments in sera of patients allergic to milk. Int Arch Allergy Immunol. 110:156-162. Savilahti E, Tainio VM, Salmenpera L, Arjomaa P, Kallio M, Perheentupa J, Siimes MA. (1991) Low colostral IgA associated with cow's milk allergy. Acta Pediatr Scan. 80:1207-1213. Selo I, Clement G, Bernard H, et al. (1999) Allergy to bovine B-lactoglobulin: specificity of human IgE to tryptic peptides. Clinical and Experimental Allergy. 29:1055-1063. Delespesse, G. Polypeptide factors from colostrum. US Patent #5,371,073 (1994). IgE (the immunoglobulin involved in allergic response) binding factors (IgE-bf) and IgE suppressor activity (IgE-SF) obtained from colostrum have been successfully used to treat allergies. Collins, AM, et al.
    [Show full text]
  • Airway Inflammation Mitochondrial Dysfunction Increases Allergic
    Mitochondrial Dysfunction Increases Allergic Airway Inflammation Leopoldo Aguilera-Aguirre, Attila Bacsi, Alfredo Saavedra-Molina, Alexander Kurosky, Sanjiv Sur and Istvan This information is current as Boldogh of October 1, 2021. J Immunol 2009; 183:5379-5387; Prepublished online 28 September 2009; doi: 10.4049/jimmunol.0900228 http://www.jimmunol.org/content/183/8/5379 Downloaded from References This article cites 61 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/183/8/5379.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 1, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Mitochondrial Dysfunction Increases Allergic Airway Inflammation1 Leopoldo Aguilera-Aguirre,*§ Attila Bacsi,*¶ Alfredo Saavedra-Molina,§ Alexander Kurosky,† Sanjiv Sur,‡ and Istvan Boldogh*2 The prevalence of allergies and asthma among the world’s population has been steadily increasing due to environmental factors.
    [Show full text]
  • Effects of Transfer Factor Supplementation on Immune
    Journal of Nutrition and Health Sciences Volume 6 | Issue 3 ISSN: 2393-9060 Research Article Open Access Effects of Transfer Factor Supplementation on Immune Reactions in Mice Vetvicka V* and Vetvickova J University of Louisville, Department of Pathology, Louisville, KY, USA *Corresponding author: Vetvicka V, University of Louisville, Department of Pathology, 511 S. Floyd, Louisville, KY 40202, USA, Tel: 5028521612, E-mail: [email protected] Citation: Vetvicka V, Vetvickova J (2019) Effects of Transfer Factor Supplementation on Immune Reactions in Mice. J Nutr Health Sci 6(3): 301 Received Date: October 7, 2019 Accepted Date: December 17, 2019 Published Date: December 19, 2019 Abstract Colostrum-derived transfer factors are among the highest potential natural immunostimulatory food supplements. In our study, we evaluated the possible effects of supplementation with various compositions that included transfer factors in phagocytosis, TNF-α and IL-2 secretion, antibody formation and NK cells activity. We found significant improvements of all these immune reactions after 7 days of supplementation. Keywords: Transfer Factor; Phagocytosis; IL-2; Cytokines; Antibodies, NK Cells Introduction The term "transfer factor/s" has various unrelated meanings in science. One definition was developed by H. Sherwood Lawrence, originated from human cells and consisted entirely of amino acids. A second use of the term transfer factor applies to a potentially different entity derived from cow colostrum or chicken egg yolk. Recently, transfer factor has been harvested from sources other than blood, and administered orally, as opposed to intravenously. This use of transfer factors from sources other than blood has not been accompanied by the same concerns associated with blood-borne diseases, since no blood is involved.
    [Show full text]
  • Pharmacological Activities and Potential Use of Bovine Colostrum
    Pharmacia 68(2): 471–477 DOI 10.3897/pharmacia.68.e65537 Review Article Pharmacological activities and potential use of bovine colostrum for peptide-based radiopharmaceuticals: A review Crhisterra Ellen Kusumaningrum1, Eva Maria Widyasari1, Maula Eka Sriyani1, Hendris Wongso1 1 Labelled Compound and Radiometry Division, Center for Applied Nuclear Science and Technology, National Nuclear Energy Agency, Jl. Tamansari 71 Bandung, West Java 40132, Indonesia Corresponding author: Hendris Wongso ([email protected]) Received 5 March 2021 ♦ Accepted 23 April 2021 ♦ Published 7 June 2021 Citation: Kusumaningrum CE, Widyasari EM, Sriyani ME, Wongso H (2021) Pharmacological activities and potential use of bovine colostrum for peptide-based radiopharmaceuticals: A review. Pharmacia 68(2): 471–477. https://doi.org/10.3897/pharmacia.68.e65537 Abstract Bovine colostrum (BC) is the initial milk produced by cows after giving birth. It has been used to treat human diseases, such as infections, inflammations, and cancers. Accumulating evidence suggests that bovine lactoferrin and bovine antibodies seem to be the most important bioactive constituents in BC. Thus, BC has also been reviewed for its potential to deliver short-term protection against coronavirus disease 2019 (COVID-19). In addition, it can potentially be explored as a precursor for peptide-based radiophar- maceuticals. To date, several bioactive peptides have been isolated from BC, including casocidin-1, casecidin 15 and 17, isracidin, caseicin A, B, and C. Like other peptides, bioactive peptides derived from BC could be used as a valuable precursor for radiopharma- ceuticals either for diagnosis or therapy purposes. This review provides bovine colostrum’s biological activities and a perspective on the potential use of peptides from BC for developing radiopharmaceuticals in nuclear medicine.
    [Show full text]
  • Review Article Cell Cycle Inhibition Without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: an Update
    The Scientific World Journal Volume 2012, Article ID 491737, 13 pages The cientificWorldJOURNAL doi:10.1100/2012/491737 Review Article Cell Cycle Inhibition without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: An Update Da-Zhi Liu and Bradley P. Ander Department of Neurology and the MIND Institute, University of California at Davis, Sacramento, CA 95817, USA Correspondence should be addressed to Da-Zhi Liu, [email protected] Received 13 October 2011; Accepted 17 November 2011 Academic Editors: F. Bareyre and B. K. Jin Copyright © 2012 D.-Z. Liu and B. P. Ander. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Since publishing our earlier report describing a strategy for the treatment of central nervous system (CNS) diseases by inhibiting the cell cycle and without disrupting neurogenesis (Liu et al. 2010), we now update and extend this strategy to applications in the treatment of cancers as well. Here, we put forth the concept of “aberrant cell cycle diseases” to include both cancer and CNS diseases, the two unrelated disease types on the surface, by focusing on a common mechanism in each aberrant cell cycle reentry. In this paper, we also summarize the pharmacological approaches that interfere with classical cell cycle molecules and mitogenic pathways to block the cell cycle of tumor cells (in treatment of cancer) as well as to block the cell cycle of neurons (in treatment of CNS diseases). Since cell cycle inhibition can also block proliferation of neural progenitor cells (NPCs) and thus impair brain neurogenesis leading to cognitive deficits, we propose that future strategies aimed at cell cycle inhibition in treatment of aberrant cell cycle diseases (i.e., cancers or CNS diseases) should be designed with consideration of the important side effects on normal neurogenesis and cognition.
    [Show full text]
  • Mitochondria-Targeted Protective Compounds in Parkinson's And
    Hindawi Publishing Corporation Oxidative Medicine and Cellular Longevity Volume 2015, Article ID 408927, 30 pages http://dx.doi.org/10.1155/2015/408927 Review Article Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases Carlos Fernández-Moriano, Elena González-Burgos, and M. Pilar Gómez-Serranillos Department of Pharmacology, Faculty of Pharmacy, University Complutense of Madrid, 28040 Madrid, Spain Correspondence should be addressed to M. Pilar Gomez-Serranillos;´ [email protected] Received 30 December 2014; Revised 25 March 2015; Accepted 27 March 2015 Academic Editor: Giuseppe Cirillo Copyright © 2015 Carlos Fernandez-Moriano´ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Mitochondria are cytoplasmic organelles that regulate both metabolic and apoptotic signaling pathways; their most highlighted functions include cellular energy generation in the form of adenosine triphosphate (ATP), regulation of cellular calcium homeostasis, balance between ROS production and detoxification, mediation of apoptosis cell death, and synthesis and metabolism of various key molecules. Consistent evidence suggests that mitochondrial failure is associated with early events in the pathogenesis of ageing-related neurodegenerative disorders including Parkinson’s disease and Alzheimer’s disease. Mitochondria-targeted protective compounds that prevent or minimize mitochondrial dysfunction constitute potential therapeutic strategies in the prevention and treatment of these central nervous system diseases. This paper provides an overview of the involvement of mitochondrial dysfunction in Parkinson’s and Alzheimer’s diseases, with particular attention to in vitro and in vivo studies on promising endogenous and exogenous mitochondria-targeted protective compounds.
    [Show full text]
  • Dairy Constituents and Neurocognitive Health in Ageing
    University of Wollongong Research Online Faculty of Social Sciences - Papers Faculty of Arts, Social Sciences & Humanities 1-1-2011 Dairy constituents and neurocognitive health in ageing David A. Camfield Swinburne University of Technology, [email protected] Lauren Owen Swinburne University of Technology Andrew Scholey Swinburne University of Technology, [email protected] Andrew Pipingas Swinburne University of Technology, [email protected] Con Stough Swinburne University of Technology, [email protected] Follow this and additional works at: https://ro.uow.edu.au/sspapers Part of the Education Commons, and the Social and Behavioral Sciences Commons Recommended Citation Camfield, David A.; Owen, Lauren; Scholey, Andrew; Pipingas, Andrew; and Stough, Con, "Dairy constituents and neurocognitive health in ageing" (2011). Faculty of Social Sciences - Papers. 487. https://ro.uow.edu.au/sspapers/487 Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [email protected] Dairy constituents and neurocognitive health in ageing Abstract Age-related cognitive decline (ARCD) and dementia are of increasing concern to an ageing population. In recent years, there has been considerable research focused on effective dietary interventions that may prevent or ameliorate ARCD and dementia. While a number of studies have considered the impact that dairy products may have on physiological health, particularly with regard to the metabolic syndrome and cardiovascular health, further research is currently needed in order to establish the impact that dairy products have in the promotion of healthy brain function during ageing. The present review considers the available evidence for the positive effects of dairy products on the metabolic syndrome and glucose regulation, with consideration of the implications for neurocognitive health.
    [Show full text]
  • Lessons Learned
    Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).
    [Show full text]
  • Bovine Colostrum: Its Constituents and Uses
    nutrients Review Bovine Colostrum: Its Constituents and Uses Raymond John Playford 1,2,* and Michael James Weiser 2 1 Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK 2 Department of R&D, PanTheryx Inc., Boulder, CO 80301, USA; [email protected] * Correspondence: [email protected]; Tel.: +44-2078827225 Abstract: Colostrum is the milk produced during the first few days after birth and contains high levels of immunoglobulins, antimicrobial peptides, and growth factors. Colostrum is important for supporting the growth, development, and immunologic defence of neonates. Colostrum is naturally packaged in a combination that helps prevent its destruction and maintain bioactivity until it reaches more distal gut regions and enables synergistic responses between protective and reparative agents present within it. Bovine colostrum been used for hundreds of years as a traditional or complementary therapy for a wide variety of ailments and in veterinary practice. Partly due to concerns about the side effects of standard Western medicines, there is interest in the use of natural-based products of which colostrum is a prime example. Numerous preclinical and clinical studies have demonstrated therapeutic benefits of bovine colostrum for a wide range of indications, including maintenance of wellbeing, treatment of medical conditions and for animal husbandry. Articles within this Special Issue of Nutrients cover the effects and use bovine colostrum and in this introductory article, we describe the main constituents, quality control and an overview of the use of bovine colostrum in health and disease. Keywords: nutraceuticals; gut repair; growth factors; injury Citation: Playford, R.J.; Weiser, M.J.
    [Show full text]
  • Therapeutics of Alzheimer's Disease: Past, Present and Future
    Neuropharmacology 76 (2014) 27e50 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Review Therapeutics of Alzheimer’s disease: Past, present and future R. Anand a,*, Kiran Dip Gill b, Abbas Ali Mahdi c a Department of Biochemistry, Christian Medical College, Vellore 632002, Tamilnadu, India b Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India c Department of Biochemistry, King George’s Medical University, Lucknow, UP, India article info abstract Article history: Alzheimer’s disease (AD) is the most common cause of dementia worldwide. The etiology is multifac- Received 29 December 2012 torial, and pathophysiology of the disease is complex. Data indicate an exponential rise in the number of Received in revised form cases of AD, emphasizing the need for developing an effective treatment. AD also imposes tremendous 26 June 2013 emotional and financial burden to the patient’s family and community. The disease has been studied over Accepted 2 July 2013 a century, but acetylcholinesterase inhibitors and memantine are the only drugs currently approved for its management. These drugs provide symptomatic improvement alone but do less to modify the disease Keywords: process. The extensive insight into the molecular and cellular pathomechanism in AD over the past few Alzheimer’s disease fi Amyloid decades has provided us signi cant progress in the understanding of the disease. A number of novel Dementia strategies that seek to modify the disease process have been developed. The major developments in this Neuropharmacology direction are the amyloid and tau based therapeutics, which could hold the key to treatment of AD in the Neurofibrillary tangles near future.
    [Show full text]
  • Oral Immunotherapy for the Treatment of Chronic Diseases and Infections
    ISSN: 2644-2957 DOI: 10.33552/OJCAM.2019.02.000533 Online Journal of Complementary & Alternative Medicine Research Article Copyright © All rights are reserved by George J Georgiou Oral Immunotherapy for the Treatment of Chronic Diseases and Infections George J Georgiou* Research Director, Worldwide Health Center, Cyprus. *Corresponding author: George J Georgiou, Research Director, Worldwide Health Received Date: September 05, 2018 [email protected]. Published Date: September 19, 2019 Center, Cyprus E-mail: Abstract Immunotherapy has recently emerged as a novel and appealing strategy for treating cancer and other acute and chronic diseases. During an infection, macrophage phagocytic cells proliferate in order to counteract the infection. withFor another the last group 20 years, the same the group-specific year. It has received component a great (Gc) deal protein-derived of attention Macrophagein the past few Activating years because Factor (GcMAF), of its proposed has received therapeutic a lot of useattention. in the In 1999, the Japanese researcher Nobuto Yamamoto published his first report mentioning the use of Gc -MAF on Tumour Bearing Mice, along immunotherapy of cancer and other diseases ranging from autism and AIDS to multiple sclerosis and lupus. There is substantial scientific evidence in the last 20 years, demonstrating that GcMAF, extracted from human blood, inhibits cancer cell proliferation in vitro, angiogenesis and tumour growth in the experimental animal, and may have a role in the immunotherapy of a variety of conditions. [1-10]. Further research has shown that blood derived GcMAF may also play a significant role in reducing the damage inflicted by chemotherapy in neurons and glial cells in vitro [11, 12].
    [Show full text]
  • New Therapeutic Targeting of Alzheimer's Disease with The
    Sochocka et al. Journal of Neuroinflammation (2019) 16:137 https://doi.org/10.1186/s12974-019-1520-6 RESEARCH Open Access New therapeutic targeting of Alzheimer’s disease with the potential use of proline- rich polypeptide complex to modulate an innate immune response - preliminary study Marta Sochocka1*, Michał Ochnik1, Maciej Sobczyński2, Iwona Siemieniec1, Beata Orzechowska1, Piotr Naporowski3 and Jerzy Leszek4 Abstract Background: The lack of effective treatment for Alzheimer’s disease (AD) stems mainly from the incomplete understanding of AD causes. Neuroinflammation has emerged as an important component of AD pathology, and a vast number of experimental and clinical data indicated a crucial role for the activation of the innate immune system in disease promotion and symptom progression. Methods: Clinical examinations of AD patients in a different stage of disease severity in correlation with the measurement of two innate immune reactions, i.e., peripheral blood leukocyte (PBLs) resistance to viral infection (vesicular stomatitis virus, VSV) ex vivo, and cytokines: TNF-α,IFN-γ,IL-1β, and IL-10, production with enzyme- linked immunosorbent assay (ELISA), have been investigated during this preliminary study before and after 4 weeks of oral treatment with dietary supplement proline-rich polypeptide complex (PRP) (120 μg of PRP/day). The potential effect of PRP on the distribution of PBLs’ subpopulations has been specified. Results: We have found a deficiency in innate immune response in AD patients. It was demonstrated for the first time that the degree of PBLs resistance to VSV infection was closely related to the stage of clinical severity of AD. Our study showed significant differences in cytokine production which pointed that in AD patients innate immune mechanisms are impaired.
    [Show full text]